Abionyx: reduced net loss in 2023

(CercleFinance.com) - Abionyx Pharma reports a net loss of 3.
52 million euros for 2023, compared with a deficit of 4.21 million the previous year, as well as a 20% reduction in its operating loss to 3.4 million on sales of 4.64 million.

Research and development costs rose to 1.52 million euros, as the company pursued the activities initiated in 2022, in particular clinical studies in renal and ophthalmology indications.

Abionyx is continuing to develop its strategic plan, and recalls that last October it carried out a capital increase, an operation which increased its financial visibility until the first quarter of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.